DK200301097A - Farmaceutiske sammensætninger med antibiotikumaktivitet - Google Patents

Farmaceutiske sammensætninger med antibiotikumaktivitet Download PDF

Info

Publication number: DK200301097A
Authority: DK; Denmark
Prior art keywords: sodium; pharmaceutical compositions; antibiotic activity; potassium; trisodium
Prior art date: 2002-08-01

Application number

DK200301097A

Other languages

English (en)

Inventor

Luca Rampoldi

Luca Pirrone

Sarah Faccin

Alessandro Grassano

Giovanni Gurrieri

Original Assignee

Zambon Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-01

Filing date

2003-07-22

Publication date

2004-02-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27638551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK200301097(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-07-22 Application filed by Zambon Spa filed Critical Zambon Spa

2004-02-02 Publication of DK200301097A publication Critical patent/DK200301097A/da

2016-01-04 Application granted granted Critical

2016-01-04 Publication of DK178348B1 publication Critical patent/DK178348B1/da

Links

239000008194 pharmaceutical composition Substances 0.000 title description 2
230000003115 biocidal effect Effects 0.000 title 1
239000001509 sodium citrate Substances 0.000 description 6
150000001875 compounds Chemical class 0.000 description 5
239000000203 mixture Substances 0.000 description 5
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
239000000126 substance Substances 0.000 description 3
239000004475 Arginine Substances 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
BIJWDXCREIQCOL-UHFFFAOYSA-K [Na+].[Na+].[Na+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O Chemical compound [Na+].[Na+].[Na+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O BIJWDXCREIQCOL-UHFFFAOYSA-K 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
229960003121 arginine Drugs 0.000 description 2
FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 2
239000001354 calcium citrate Substances 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 2
BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 2
VLYFRFHWUBBLRR-UHFFFAOYSA-L potassium;sodium;carbonate Chemical compound [Na+].[K+].[O-]C([O-])=O VLYFRFHWUBBLRR-UHFFFAOYSA-L 0.000 description 2
ASHGTUMKRVIOLH-UHFFFAOYSA-L potassium;sodium;hydrogen phosphate Chemical compound [Na+].[K+].OP([O-])([O-])=O ASHGTUMKRVIOLH-UHFFFAOYSA-L 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
229940001593 sodium carbonate Drugs 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
235000013337 tricalcium citrate Nutrition 0.000 description 2
229940078499 tricalcium phosphate Drugs 0.000 description 2
229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
235000019731 tricalcium phosphate Nutrition 0.000 description 2
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
229940038773 trisodium citrate Drugs 0.000 description 2
SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
108010062796 arginyllysine Proteins 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229960003975 potassium Drugs 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
AVTYONGGKAJVTE-OLXYHTOASA-L potassium L-tartrate Chemical compound [K+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O AVTYONGGKAJVTE-OLXYHTOASA-L 0.000 description 1
AKEKKCGPLHMFCI-UHFFFAOYSA-L potassium sodium hydrogen carbonate Chemical compound [Na+].[K+].OC([O-])=O.OC([O-])=O AKEKKCGPLHMFCI-UHFFFAOYSA-L 0.000 description 1
239000001472 potassium tartrate Substances 0.000 description 1
229940111695 potassium tartrate Drugs 0.000 description 1
235000011005 potassium tartrates Nutrition 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Inorganic Chemistry (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Saccharide Compounds (AREA)

Description

P a t e n t k r a v : 1. Anvendelse af et stof valgt blandt: trinatrium- eller trikaliumcitrat monosurt natrium- eller kaliumcitrat trinatrium- eller trikaliumphosphat monosurt natrium- eller kaliumphosphat natrium- eller kaliumcarbonat natrium-eller kaliumbicarbonat natrium- eller kaliumtartrat arginin lysin eller blandinger af disse, til stabilisering af Fosfomycin Tromethamol. 2. Anvendelse som stabilisator af en forbindelse ifølge krav 1, k ende-tegnet ved, at forbindelsen vælges blandt trinatriumcitrat, natrium-carbonat eller arginin. 3. Anvendelse af en forbindelse ifølge krav 1,kendetegnet ved, at forbindelsen anvendes i et molforhold i forhold til FT-indholdet på mellem 10 % og 100 %, fortrinsvis mellem 30 % og 70 %, og endnu mere foretrukket ca. 50 %. 4. Farmaceutiske sammensætninger indeholdende Fosfomycin Tromethamol, en forbindelse valgt blandt: trinatrium- eller trikaliumcitrat monosurt natrium- eller kaliumcitrat trinatrium- eller trikaliumphosphat monosurt natrium- eller kaliumphosphat natrium- eller kaliumcarbonat natrium- eller kaliumbicarbonat natrium- eller kaliumtartrat arginin lysin eller blandinger deraf, og egnede excipienser til farmaceutiske anvendelse. 5. Sammensætning ifølge krav 4, kendetegnet ved, at den er i form af opløseligt granulat. 6. Sammensætning ifølge krav 5, kendetegnet ved, at den indeholdte mængde FT til enkelt dosis er 5,631 g. 7. Sammensætning ifølge krav 1,kendetegnet ved, at stoffet med stabiliserende aktivitet vælges blandt trinatriumcitrat, natriumcarbonat og arginin. 8. Sammensætning ifølge krav 1,kendetegnet ved, at stoffet med stabiliserende aktivitet anvendes i et molforhold i forhold til FT-indholdet på mellem 10 % og 100 %, fortrinsvis mellem 30 % og 70 %, og endnu mere foretrukket ca. 50 %.

DK200301097A 2002-08-01 2003-07-22 Farmaceutiske sammensætninger med antibiotikumaktivitet DK178348B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT001725A ITMI20021725A1 (it)	2002-08-01	2002-08-01	Composizioni farmaceutiche ad attivita' antibiotica.
ITMI20021725		2002-08-01

Publications (2)

Publication Number	Publication Date
DK200301097A true DK200301097A (da)	2004-02-02
DK178348B1 DK178348B1 (da)	2016-01-04

Family

ID=27638551

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK200301097A DK178348B1 (da)	2002-08-01	2003-07-22	Farmaceutiske sammensætninger med antibiotikumaktivitet

Country Status (29)

Country	Link
US (1)	US7303755B2 (da)
JP (1)	JP4395338B2 (da)
KR (1)	KR100966977B1 (da)
AT (1)	AT500521B1 (da)
BE (1)	BE1017903A3 (da)
BR (1)	BRPI0302496C1 (da)
CA (1)	CA2434927C (da)
CH (1)	CH696718A5 (da)
CO (1)	CO5480297A1 (da)
CZ (1)	CZ305023B6 (da)
DE (1)	DE10334820B4 (da)
DK (1)	DK178348B1 (da)
ES (1)	ES2224869B1 (da)
FI (1)	FI120080B (da)
FR (1)	FR2852845B1 (da)
GR (1)	GR20030100300A (da)
HR (1)	HRP20030618B1 (da)
HU (1)	HU230575B1 (da)
IL (1)	IL156615A (da)
IT (1)	ITMI20021725A1 (da)
NL (1)	NL1023790C2 (da)
PL (1)	PL209644B1 (da)
PT (1)	PT102995B (da)
RU (1)	RU2333000C2 (da)
SE (1)	SE527466C2 (da)
SI (1)	SI21259B (da)
SK (1)	SK287201B6 (da)
TR (1)	TR200301248A2 (da)
ZA (1)	ZA200305040B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE740685C (de) *	1941-04-11	1943-10-26	Voigt & Haeffner Ag	Viertakt-Regelschalter fuer Parallel-, Einzel- und Reihenschaltung von Heizwiderstaenden
ES2244333B1 (es) *	2004-05-18	2006-08-01	Simbec Iberica, Sl	Preparado farmaceutico oral de fosfomicina estable y apto para diabeticos.
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA030999B1 (ru)	2009-10-02	2018-10-31	Бёрингер Ингельхайм Интернациональ Гмбх	Применение фармацевтической композиции, включающей ингибитор дпп-4 и гидрохлорид метформина
EA021876B1 (ru) *	2010-09-20	2015-09-30	ЛИМОНОВ, Виктор Львович	Фармацевтическая композиция антимикробного и противовоспалительного действия для парентерального введения, способ ее получения
ES2385158B1 (es) *	2010-12-24	2013-05-28	Arafarma Group, S.A.	Composición farmacéutica de fosfomicina
CN102579466A (zh) *	2011-01-10	2012-07-18	王乐	一种磷霉素或磷霉素精氨酸盐与精氨酸的组合物
US8604078B2 (en) *	2011-04-06	2013-12-10	Carlos Picornell Darder	Fosfomycin pharmaceutical composition
US20140323443A1 (en) *	2013-04-30	2014-10-30	Fresenius Kabi Usa, Llc	Tigecycline formulations
ITTO20130839A1 (it) *	2013-10-16	2015-04-17	C & G Farmaceutici S R L	Composizione a base di fosfomicina trometamolo
DE102014218913A1 (de)	2014-09-19	2016-03-24	Heraeus Medical Gmbh	Verfahren zur Herstellung eines antibiotischen Polymehtylmethacrylat-Knochenzementpulvers und ein antibiotisches Polymethtylmethacrylat-Knochenzementpulver
CN104546689B (zh) *	2015-01-07	2019-01-25	同方药业集团有限公司	一种含有甲硝唑的药物组合物
WO2017111718A1 (en)	2015-12-25	2017-06-29	Yusuf Toktamiş Öğün	The formulation comprising phosphomycine and ascorbic acid for the treatment of bacterial urinary system infections
WO2017211979A1 (en)	2016-06-10	2017-12-14	Boehringer Ingelheim International Gmbh	Combinations of linagliptin and metformin
CA3147662A1 (en)	2021-02-10	2022-08-10	Labiana Health, S.L.	New fosfomycin tablet formulations

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3852434A (en)	1970-09-11	1974-12-03	Merck & Co Inc	Potentiation of ({31 ) cis-1,2-epoxypropyl)phosphonic acid and analogues thereof
IT1161974B (it)	1978-02-02	1987-03-18	Italchemi Spa	Derivti dell acido cis.i 2 epossipropilfosfonico loro procedimento di preparazione e composizioni farmaceutiche che li contengono
IT1112282B (it)	1978-07-19	1986-01-13	Zambon Spa	Bis-(2-ammonio-2-idrossimetil-1,3-propandiolo)(2r-cis)-(3-metilossiranil)fosfonato
IT1124610B (it)	1979-10-18	1986-05-07	Zambo Spa	Mono(2-ammonio-2-idrossimetil-1,3-propandiolo) (2r-cis)-(o-metilossiranil)fosfonato
JPS59104326A (ja)	1982-12-04	1984-06-16	Toyo Jozo Co Ltd	マクロライド抗生物質の安定な経口用製剤および安定化法
CH660305A5 (de)	1984-10-05	1987-04-15	Schering Spa	Wasserloesliche pharmazeutische zusammensetzungen auf der basis von salzen der (-)cis-1,2-epoxypropylphosphonsaeure mit aminosaeuren.
EP0390930B1 (en) *	1988-09-26	1993-03-03	Teijin Limited	Stable aqueous preparation of active vitamin d 3
IT1231013B (it)	1989-07-27	1991-11-08	Zambon Spa	Mono (2 ammonio 2 idrossimetil 1,3 propandiolo)(2r,cis) 1,2 epossipropil fosfonato avente migliorate caratteristiche di stabilita' e lavorabilita'.
US5191094A (en)	1989-07-27	1993-03-02	Zambon Group S.P.A.	Mono (2-ammonium-2-hydroxymethyl-1,3-propanediol) (2R,cis)-1,2-epoxypropyl-phosphonate with improved characteristics of stability and processing
IT1244543B (it)	1991-02-01	1994-07-15	La Fa Re Srl	Uso topico della fosfomicina e dei suoi sali nella terapia delle infezioni vaginali e/o uretrali
FR2690340B1 (fr)	1992-04-24	1995-02-24	Scr Newmed	Nouveau procédé de stabilisation des préparations pharmaceutiques liquides et les compositions pharmaceutiques ainsi stabilisées en résultant.
CA2091152C (en)	1993-03-05	2005-05-03	Kirsten Westesen	Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
US5885486A (en) *	1993-03-05	1999-03-23	Pharmaciaand Upjohn Ab	Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
DE4327063A1 (de) *	1993-08-12	1995-02-16	Kirsten Dr Westesen	Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
US5693337A (en) *	1994-07-13	1997-12-02	Wakamoto Pharmaceutical Co., Ltd.	Stable lipid emulsion
JPH09183730A (ja) *	1995-05-10	1997-07-15	Meiji Seika Kaisha Ltd	ホスホマイシン鏡像異性体を含んでなる医薬
DE19712565A1 (de)	1997-03-25	1998-10-01	Thomas W Dr Stief	Arzneimittel auf der Basis eines Singulett-Sauerstoff erzeugenden Agenzes
WO1999017782A1 (en) *	1997-10-03	1999-04-15	Meiji Seika Kaisha Ltd.	Composition for treatment of diabetes and treatment of diabetes
RU2133122C1 (ru) *	1998-10-14	1999-07-20	Научно-исследовательский институт биомедицинской химии РАМН	Композиция, обладающая свойствами репарировать биологические мембраны
CA2413251C (en) *	2000-06-21	2012-06-12	Cubist Pharmaceuticals, Inc.	Compositions and methods to improve the oral absorption of antimicrobial agents
US6699505B2 (en) *	2000-10-17	2004-03-02	Massachusetts Institute Of Technology	Method of increasing the efficacy of antibiotics by compexing with cyclodextrins
US7378408B2 (en)	2001-11-30	2008-05-27	Pfizer Inc.	Methods of treatment and formulations of cephalosporin
TW200403240A (en) *	2002-06-28	2004-03-01	Upjohn Co	Difluorothioacetamides of oxazolidinones as antibacterial agents

2002
- 2002-08-01 IT IT001725A patent/ITMI20021725A1/it unknown
2003
- 2003-06-24 IL IL156615A patent/IL156615A/en active IP Right Grant
- 2003-06-27 ZA ZA200305040A patent/ZA200305040B/xx unknown
- 2003-07-01 NL NL1023790A patent/NL1023790C2/nl not_active IP Right Cessation
- 2003-07-07 PT PT102995A patent/PT102995B/pt active IP Right Grant
- 2003-07-10 US US10/615,781 patent/US7303755B2/en not_active Expired - Lifetime
- 2003-07-10 CA CA2434927A patent/CA2434927C/en not_active Expired - Lifetime
- 2003-07-11 CO CO03058787A patent/CO5480297A1/es active IP Right Grant
- 2003-07-15 GR GR20030100300A patent/GR20030100300A/el unknown
- 2003-07-15 CH CH01238/03A patent/CH696718A5/it not_active IP Right Cessation
- 2003-07-16 FI FI20031078A patent/FI120080B/fi active IP Right Grant
- 2003-07-22 DK DK200301097A patent/DK178348B1/da not_active IP Right Cessation
- 2003-07-23 JP JP2003200437A patent/JP4395338B2/ja not_active Expired - Lifetime
- 2003-07-24 SI SI200300194A patent/SI21259B/sl active Search and Examination
- 2003-07-25 SE SE0302129A patent/SE527466C2/sv not_active IP Right Cessation
- 2003-07-28 BE BE2003/0427A patent/BE1017903A3/fr not_active IP Right Cessation
- 2003-07-28 AT AT0119103A patent/AT500521B1/de not_active IP Right Cessation
- 2003-07-29 BR BRPI0302496A patent/BRPI0302496C1/pt not_active IP Right Cessation
- 2003-07-30 HR HR20030618A patent/HRP20030618B1/xx not_active IP Right Cessation
- 2003-07-30 ES ES200301811A patent/ES2224869B1/es not_active Expired - Fee Related
- 2003-07-30 DE DE10334820.4A patent/DE10334820B4/de not_active Expired - Lifetime
- 2003-07-31 SK SK976-2003A patent/SK287201B6/sk not_active IP Right Cessation
- 2003-07-31 HU HU0302441A patent/HU230575B1/hu unknown
- 2003-07-31 KR KR1020030053032A patent/KR100966977B1/ko not_active Expired - Lifetime
- 2003-07-31 PL PL361518A patent/PL209644B1/pl unknown
- 2003-07-31 RU RU2003124299/15A patent/RU2333000C2/ru active
- 2003-07-31 FR FR0309459A patent/FR2852845B1/fr not_active Expired - Lifetime
- 2003-08-01 TR TR2003/01248A patent/TR200301248A2/xx unknown
- 2003-08-01 CZ CZ2003-2096A patent/CZ305023B6/cs not_active IP Right Cessation

Also Published As

Publication number	Publication date
KR100966977B1 (ko)	2010-06-30
HUP0302441A2 (hu)	2005-07-28
NL1023790C2 (nl)	2004-03-10
CA2434927C (en)	2011-10-18
BE1017903A3 (fr)	2009-11-03
HRP20030618B1 (hr)	2011-10-31
SE0302129L (sv)	2004-02-02
PT102995B (pt)	2004-07-30
BR0302496A (pt)	2004-08-24
BRPI0302496B8 (pt)	2016-09-13
SE0302129D0 (sv)	2003-07-25
DE10334820A1 (de)	2004-03-11
CO5480297A1 (es)	2005-01-28
AT500521B1 (de)	2007-11-15
SE527466C2 (sv)	2006-03-14
HU0302441D0 (en)	2003-09-29
US7303755B2 (en)	2007-12-04
JP4395338B2 (ja)	2010-01-06
KR20040012569A (ko)	2004-02-11
GR20030100300A (el)	2004-04-22
IL156615A (en)	2008-11-26
SI21259B (sl)	2012-12-31
HRP20030618A2 (en)	2004-04-30
CZ305023B6 (cs)	2015-04-01
SK287201B6 (sk)	2010-03-08
ZA200305040B (en)	2004-05-11
FI120080B (fi)	2009-06-30
CH696718A5 (it)	2007-10-31
AT500521A1 (de)	2006-01-15
PL209644B1 (pl)	2011-09-30
RU2003124299A (ru)	2005-01-20
CA2434927A1 (en)	2004-02-01
HU230575B1 (hu)	2017-02-28
CZ20032096A3 (cs)	2004-03-17
SI21259A (sl)	2004-02-29
DK178348B1 (da)	2016-01-04
FI20031078A0 (fi)	2003-07-16
RU2333000C2 (ru)	2008-09-10
DE10334820B4 (de)	2020-02-06
PL361518A1 (pl)	2004-02-09
NL1023790A1 (nl)	2004-02-03
ES2224869B1 (es)	2007-07-01
IL156615A0 (en)	2004-01-04
FR2852845A1 (fr)	2004-10-01
TR200301248A2 (tr)	2004-02-23
FI20031078A7 (fi)	2004-02-02
BRPI0302496C1 (pt)	2021-05-25
SK9762003A3 (en)	2004-02-03
ITMI20021725A1 (it)	2002-10-31
PT102995A (pt)	2004-02-27
ES2224869A1 (es)	2005-03-01
JP2004067682A (ja)	2004-03-04
BRPI0302496B1 (pt)	2015-07-28
US20040022866A1 (en)	2004-02-05
FR2852845B1 (fr)	2006-01-06

Legal Events

Date	Code	Title	Description
2023-07-23	PUP	Patent expired	Expiry date: 20230722

Publication	Publication Date	Title
RU2003124299A (ru)	2005-01-20	Фармацевтические составы, обладающие антибиотической активностью
WO2005016365A3 (en)	2005-04-21	Liquid, aqueous pharmaceutical composition of factor vii polypeptides
NO20064347L (no)	2006-09-26	Substituerte 1,2,3,4-tetrahydroisokinolinderivater
DE60130023D1 (de)	2007-09-27	Behandlung der nebenwirkungen von statinen
DK1008588T3 (da)	2003-07-28	11,15-O-dialkylprostaglandin E derivater, fremgangsmåder til fremstilling deraf og farmaceutiske sammensætninger, der omfatter dem som virksom bestanddel
BRPI0508579A (pt)	2007-08-14	composto, composição farmacêutica, e, uso de um composto
NO20044451L (no)	2004-11-04	Lav-doserings flytende entecavir-formuleringer og deres anvendelse
EP1552756A4 (en)	2005-11-16	DRINK
BR0209811A (pt)	2004-06-01	Mistura herbicida compreendendo um derivado de benzoìla, um fertilizante contendo nitrogênio e um adjuvante
WO2003004048A1 (fr)	2003-01-16	Compositions destinees a l'administration par voie nasale d'insuline
US4046879A (en)	1977-09-06	Antiviral compositions
DK2068842T4 (da)	2015-10-26	Aktivt stof og trimagnesiumdicitrat som stabiliserede faste lægemiddelformer, der indeholder tørremiddel, og fremgangsmåde til fremstilling deraf
HUE009867T2 (da)	2011-05-30
WO2003075834A3 (en)	2004-04-01	Activated protein c formulations
TW200505469A (en)	2005-02-16	Glycyrrhizin containing pharmaceutical composition
JPS57100177A (en)	1982-06-22	Mixed agent composition of amino acid with saccharide
JPS59137402A (ja)	1984-08-07	安定化された殺虫組成物
NO20062478L (no)	2006-06-23	Fungicidale blandinger for kontrollering av ris patogener
JPS59204110A (ja)	1984-11-19	安定化された殺虫組成物
RU2003117105A (ru)	2005-02-10	Состав для обработки материалов
JP2005187367A (ja)	2005-07-14	殺菌剤組成物
RU98123501A (ru)	2000-10-10	Новые фунгицидные композиции, содержащие 2-имидазолин-5-он
JPS588090A (ja)	1983-01-18	クロルエチルニトロソウレア化合物の安定化法
JPH11130609A (ja)	1999-05-18	抗菌剤組成物
KR830003874A (ko)	1983-06-30	제초제 조성물